Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Briumvi (ublituximab-xiiy)
i
Other names:
TGTX-1101, LFB-R603, TG-1101, LFB R603, LFBR 603, LFBR-603, EMAB-6, R603, TG20
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Trials
Company:
Ildong, LFB SA, Neuraxpharm, TG Therap
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
F007 (rituximab biosimilar) (0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
(0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
umbralisib + ublituximab-xiiy
Sensitive: B - Late Trials
umbralisib + ublituximab-xiiy
Sensitive
:
B
umbralisib + ublituximab-xiiy
Sensitive: B - Late Trials
umbralisib + ublituximab-xiiy
Sensitive
:
B
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
IL2 elevation
Mantle Cell Lymphoma
IL2 elevation
Mantle Cell Lymphoma
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
IL6 elevation
Mantle Cell Lymphoma
IL6 elevation
Mantle Cell Lymphoma
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
TNFA elevation
Mantle Cell Lymphoma
TNFA elevation
Mantle Cell Lymphoma
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.